Table 3.
Neisseria gonorrhoeae isolates in Euro-GASP from 2009 to 2016 by anatomical site of infection, and resistance combined with decreased susceptibility to ceftriaxone, and resistance to cefixime, azithromycin, and ciprofloxacin
| Site of infection | Ceftriaxone | Cefixime | Azithromycin | Ciprofloxacin | |||||
|---|---|---|---|---|---|---|---|---|---|
| No of tested | DS No (%) | R No (%) | No of tested | R No (%) | No of tested | R No (%) | No of tested | R No (%) | |
| Urogenital | 12,113 | 1264 (10.4) | 17 (0.1) | 12,063 | 575 (4.8) | 12,062 | 872 (7.2) | 12,102 | 6508 (53.8) |
| Female | 2154 | 185 (8.6) | 0 (0.0) | 2154 | 96 (4.5) | 2153 | 117 (5.4) | 2153 | 993 (46.1) |
| Males_Hetero | 3343 | 415 (12.4) | 5 (0.1) | 3307 | 196 (5.9) | 3302 | 284 (8.6) | 3343 | 1921 (57.5) |
| Males_MSM | 1928 | 172 (8.9) | 0 (0.0) | 1917 | 57 (3.0) | 1921 | 134 (7.0) | 1926 | 900 (46.7) |
| Males_Other/UNK | 4621 | 485 (10.5) | 12 (0.3) | 4618 | 222 (4.8) | 4619 | 334 (7.2) | 4613 | 2653 (57.5) |
| Unknown | 67 | 7 | 0 | 67 | 4 | 67 | 3 | 67 | 41 |
| Anorectal | 1822 | 149 (8.2) | 1 (0.1) | 1822 | 35 (1.9) | 1822 | 118 (6.5) | 1822 | 774 (42.5) |
| Female | 113 | 15 (13.3) | 0 (0.0) | 113 | 9 (8.0) | 113 | 10 (8.9) | 113 | 61 (54.0) |
| Males_Hetero | 23 | 4 (17.4) | 0 (0.0) | 23 | 1 (4.4) | 23 | 3 (13.0) | 23 | 10 (43.5) |
| Males_MSM | 1357 | 99 (7.3) | 1 (0.1) | 1357 | 18 (1.3) | 1357 | 78 (5.8) | 1357 | 556 (41.0) |
| Males_Other/UNK | 316 | 29 (9.2) | 0 (0.0) | 316 | 6 (1.9) | 316 | 26 (8.2) | 316 | 140 (44.3) |
| Unknown | 13 | 2 | 0 | 13 | 1 | 13 | 1 | 13 | 7 |
| Pharyngeal | 883 | 72 (8.2) | 2 (0.2) | 883 | 22 (2.5) | 883 | 73 (8.3) | 883 | 365 (41.3) |
| Female | 134 | 20 (14.9) | 0 (0.0) | 134 | 10 (7.5) | 134 | 14 (10.5) | 134 | 66 (49.3) |
| Males_Hetero | 26 | 2 (7.7) | 0 (0.0) | 26 | 2 (7.7) | 26 | 0 (0.0) | 26 | 16 (61.5) |
| Males_MSM | 542 | 25 (4.6) | 1 (0.2) | 542 | 6 (1.1) | 542 | 43 (7.9) | 542 | 202 (37.3) |
| Males_Other/UNK | 175 | 24 (13.7) | 0 (0.0) | 175 | 1 (0.6) | 175 | 13 (7.4) | 175 | 78 (44.6) |
| Unknown | 6 | 1 | 1 | 6 | 3 | 6 | 3 | 6 | 3 |
| Other | 372 | 22 (5.9) | 0 (0.0) | 372 | 13 (3.5) | 372 | 22 (5.9) | 372 | 187 (50.3) |
| Female | 41 | 3 (7.3) | 0 (0.0) | 41 | 1 (2.4) | 41 | 1 (2.4) | 41 | 16 (39.0) |
| Males_Hetero | 40 | 5 (12.5) | 0 (0.0) | 40 | 4 (10.0) | 40 | 2 (5.0) | 40 | 26 (65.0) |
| Males_MSM | 26 | 0 (0.0) | 0 (0.0) | 26 | 0 (0.0) | 26 | 0 (0.0) | 26 | 11 (42.3) |
| Males_Other/UNK | 263 | 14 (5.3) | 0 (0.0) | 263 | 8 (3.0) | 263 | 19 (7.2) | 263 | 134 (51.0) |
| Unknown | 2 | 0 | 0 | 2 | 0 | 2 | 0 | 2 | 0 |
| Unknown | 613 | 76 (12.4) | 6 (1.0) | 611 | 27 (4.4) | 613 | 33 (5.4) | 613 | 323 (52.7) |
| Female | 94 | 9 (9.6) | 0 (0.0) | 93 | 1 (1.1) | 94 | 1 (1.1) | 94 | 45 (47.9) |
| Males_Hetero | 32 | 7 (21.9) | 0 (0.0) | 32 | 3 (9.4) | 32 | 3 (9.4) | 32 | 17 (53.1) |
| Males_MSM | 86 | 1 (1.2) | 0 (0.0) | 86 | 1 (1.2) | 86 | 2 (2.3) | 86 | 31 (36.1) |
| Males_Other/UNK | 305 | 35 (11.5) | 1 (0.3) | 304 | 10 (3.3) | 305 | 23 (7.5) | 305 | 172 (56.4) |
| Unknown | 96 | 24 | 5 | 96 | 12 | 96 | 4 | 96 | 58 |
| Total | 15,803 | 1583 (10.0) | 26 (0.2) | 15,751 | 672 (4.3) | 15,752 | 1118 (7.1) | 15,792 | 8157 (51.7) |
No Number, R Resistance, DS Decreased susceptibility, UNK Unknown sexual orientation